Every year, thousands of promising therapeutic discoveries stall somewhere between the lab bench and the clinic. The science is sound. The mechanism is proven. But something in the translation – the process of turning a discovery into a deliverable therapy – breaks down. This “translation gap” is one of the most persistent and costly problems in biotechnology today, and it’s the subject Micregen will be tackling head-on in Shanghai this September.
On 13th September, Robert Mitchell will join a roundtable discussion titled “Bridging the Translation Gap” at the Pujiang Innovation Forum, hosted by the Shanghai Synbio Innovation Centre (SSIC). The forum brings together researchers, industry leaders and policymakers from across the global synthetic biology and life sciences community to address exactly this challenge: how do we move faster and more reliably from early-stage innovation to real-world impact?
Why This Conversation Matters Now
Cell-free biology sits at an interesting inflection point in this story. Traditional cell-based systems have long dominated therapeutic development, but they come with well-known constraints – slow iteration cycles, complex manufacturing, and significant regulatory overhead. Cell-free platforms offer a different path: faster prototyping, simplified production, and a level of control that can meaningfully shorten the distance between concept and clinic.
That’s precisely the territory Micregen operates in, and it’s why a seat at this particular table matters. The roundtable isn’t just an opportunity to showcase where cell-free therapeutic development stands today – it’s a chance to engage directly with the people shaping policy, funding and partnership decisions across the region’s fast-growing biotech sector.
What to Expect
The discussion will explore practical questions facing translational science: What infrastructure is missing? Where do promising technologies most often lose momentum? And what does effective collaboration between academic innovators, industry and investors actually look like in practice?
Robert’s contribution will draw on Micregen’s own experience navigating these exact challenges – building a cell-free therapeutic platform designed from the outset with translatability in mind, rather than retrofitting a lab discovery for manufacturing and clinical use after the fact.
Get Involved
If you’re attending the Pujiang Innovation Forum, or simply have a stake in solving the translation gap, we’d welcome the conversation. Reach out to Robert directly to arrange a meeting in Shanghai.
Micregen will also be attending BioShanghai Week 2026 immediately following the forum – more on that soon.